REZILIENT3 randomized 285 previously untreated adults globally to zipalertinib plus platinum chemotherapy versus chemotherapy alone, using PFS as the primary endpoint in advanced/metastatic ...
The FDA granted accelerated approval to RP1 (vusolimogene oderparepvec; Tudriqev), an oncolytic virus therapy, in combination ...
The FDA has cleared an investigational new drug (IND) application for Bria-PROS+, a personalized, off-the-shelf, whole-cell ...
Mark Agulnik, MD, discusses the trend away from surgery and toward targeted treatment of progressive desmoid tumors, and how ...
Phase 3 SENOMAC randomized 2766 patients across five countries to completion ALND vs omission after up to two sentinel-node ...
HR-positive disease accounts for approximately 70% to 80% of breast cancer diagnoses and carries a risk of recurrence that ...
Sagar Lonial, MD, discusses why to take an individualized approach despite the trial's findings supporting discontinuation of lenalidomide at 2 years. Sagar Lonial, MD, of the Winship Cancer Institute ...
During a live event, Sikander Ailawadhi, MD, and participants discussed how the route of CD38-antibody delivery, including a newly approved on-body injector, is shaping frontline regimen selection for ...
IMMUNO-BIOMAP targets the clinical uncertainty around who benefits from first-line immunotherapy, who experiences early failure, and whether fixed two-year treatment durations are necessary in ...
The FDA issued a complete response letter (CRL) to a new drug application (NDA) for 177 Lu-edotreotide (ITM-11) for the treatment of patients with gastroenteropancreatic neuroendocrine tumors ...
City of Hope's Dr Ravi Salgia explains a new national trial using biomarkers to predict immunotherapy success in advanced non ...
FDA tentatively OKs cabozantinib capsules for RCC, HCC and epNET, with dose-conversion guidance, error warning and improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results